PubMed 22962027 TB-4 Phase 1 human safety first-in-human randomized, double-blind, single- and multiple-dose Phase 1 of recombinant human thymosin 4 in healthy volunteers, no serious adverse events: PubMed 34346165
If these develop while taking supplements, they warrant medical assessment to rule out ongoing deficiency or other neurological conditions
Beginning the peptide within the first few days may optimize outcomes by enhancing the early inflammatory response and subsequent proliferative healing
A relatively unknown antioxidant, alpha-lipoic acid, may be more potent than vitamins C and E
If the symptoms get worse and restrict normal activities and quality of life, surgery may be necessary
Storage: After first use Important Once the peptides are reconstituted (mixed with bacteriostatic water), they must be stored in the fridge to maintain stability